Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment

The maximum response and 10-year survival rate for metastatic melanoma patients treated with standardised chemotherapy is still less than 15% and 10%, respectively. In contrast, oncogene targeting was found a promising tool for killing of BRAF(V600) mutated melanoma cells. Nevertheless, despite impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdmann, Sarah, Seidel, Diana, Jahnke, Heinz-Georg, Eichler, Marie, Simon, Jan-Christoph, Robitzki, Andrea A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328535/
https://www.ncbi.nlm.nih.gov/pubmed/30631106
http://dx.doi.org/10.1038/s41598-018-37188-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328535/
https://www.ncbi.nlm.nih.gov/pubmed/30631106
http://dx.doi.org/10.1038/s41598-018-37188-0

Ejemplares similares